Novel 4-chloro-N-phenyl Benzamide Derivatives as p38α Mitogenactivated
Protein Kinase Inhibitors for Treating Cancer, COVID-19, and
Other Diseases

Surya   K.   De

Abstract

The present disclosure relates to p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the p38α mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereof for treating various diseases such as cancer, rheumatoid arthritis, amyotrophic lateral sclerosis, cystic fibrosis, cardiovascular disease, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), asthma, COVID-19, acute respiratory distress syndrome (ARDS), and acute lung injury (ALI).

Keywords: N-Phenyl benzamide, p-38 MAPK, cancer, COVID-19, rheumatoid arthritis, inflammatory pain.

« Previous Next »

[1]
Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science  1994; 265(5173): 808-11.
 [http://dx.doi.org/10.1126/science.7914033] [PMID: 7914033]

[2]
Denny WA. Inhibitors and activators of the p38 Mitogen-Activated MAP Kinase (MAPK) family as drugs to treat cancer and inflammation. Curr Cancer Drug Targets  2022; 22(3): 209-20.
 [http://dx.doi.org/10.2174/1568009622666220215142837] [PMID: 35168519]

[3]
García-Hernández L, García-Ortega MB, Ruiz-Alcalá G, Carrillo E, Marchal JA, García MÁ. The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci  2021; 23(1): 370.
 [http://dx.doi.org/10.3390/ijms23010370] [PMID: 35008796]

[4]
Maik-Rachline G, Wortzel I, Seger R. Alternative splicing of MAPKs in the regulation of signaling specificity. Cells  2021; 10(12): 3466.
 [http://dx.doi.org/10.3390/cells10123466] [PMID: 34943973]

[5]
Wang L, Xia Z, Tang W, et al. p38 activation and viral infection. Expert Rev Mol Med  2022; 24: e4.
 [http://dx.doi.org/10.1017/erm.2021.29] [PMID: 35060846]

[6]
Chander Y, Kumar R, Khandelwal N, et al. Role of p38 mitogen‐activated protein kinase signalling in virus replication and potential for developing broad spectrum antiviral drugs. Rev Med Virol  2021; 31(5): 1-16.
 [http://dx.doi.org/10.1002/rmv.2217] [PMID: 33450133]

[7]
Grimes JM, Grimes KV. p38 MAPK inhibition: A promising therapeutic approach for COVID-19. J Mol Cell Cardiol  2020; 144: 63-5.
 [http://dx.doi.org/10.1016/j.yjmcc.2020.05.007] [PMID: 32422320]

[8]
Shah NG, Tulapurkar ME, Ramarathnam A, et al. Novel noncatalytic substrate selective p38α-specific MAPK inhibitors with endothelial stabilizing and anti-inflammatory activity. J Immunol  2017; 198(8): 3296-306.
 [http://dx.doi.org/10.4049/jimmunol.1602059] [PMID: 28298524]

[9]
Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs  2009; 18(12): 1893-905.
 [http://dx.doi.org/10.1517/13543780903321490] [PMID: 19852565]

[10]
Malekinejad Z, Baghbanzadeh A, Nakhlband A, et al. Recent clinical findings on the role of kinase inhibitors in COVID-19 management. Life Sci  2022; 306: 120809.
 [http://dx.doi.org/10.1016/j.lfs.2022.120809] [PMID: 35841979]

[11]
Cioccarelli C, Sánchez-Rodríguez R, Angioni R, et al. IL1β promotes TMPRSS2 expression and SARS-CoV-2 cell entry through the p38 MAPK-GATA2 Axis. Front Immunol  2021; 12: 781352.
 [http://dx.doi.org/10.3389/fimmu.2021.781352] [PMID: 34950146]

[12]
Valipour M, Irannejad H, Emami S. Application of emetine in SARS-CoV-2 treatment: regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications. Cell Cycle  2022; 21(22): 1-8.
 [http://dx.doi.org/10.1080/15384101.2022.2100575] [PMID: 35852390]

[13]
Ma Z, Li X, Fan RLY, et al. A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4. Stem Cell Reports  2022; 17(3): 538-55.
 [http://dx.doi.org/10.1016/j.stemcr.2022.01.015] [PMID: 35180397]

[14]
Alshehade S, Alshawsh MA, Murugaiyah V, et al. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions. Life Sci  2022; 305: 120732.
 [http://dx.doi.org/10.1016/j.lfs.2022.120732] [PMID: 35760093]

[15]
Kudaravalli S, den Hollander P, Mani SA. Role of p38 MAP kinase in cancer stem cells and metastasis. Oncogene  2022; 41(23): 3177-85.
 [http://dx.doi.org/10.1038/s41388-022-02329-3] [PMID: 35501462]

[16]
Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: Preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther  2008; 327(3): 610-9.
 [http://dx.doi.org/10.1124/jpet.108.139006] [PMID: 18776065]

Rights & Permissions Print Cite

Article Metrics

25

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574892818666221202111605	Print ISSN 1574-8928
Publisher Name Bentham Science Publisher	Online ISSN 2212-3970

Recent Patents on Anti-Cancer Drug Discovery

Novel 4-chloro-N-phenyl Benzamide Derivatives as p38α Mitogenactivated Protein Kinase Inhibitors for Treating Cancer, COVID-19, and Other Diseases

Abstract

Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research

Recent Patents on Anti-Cancer Drug Discovery

Novel 4-chloro-N-phenyl Benzamide Derivatives as p38α Mitogenactivated Protein Kinase Inhibitors for Treating Cancer, COVID-19, and Other Diseases

Abstract

Call for Papers in Thematic Issues

Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research

Related Journals

Related Books

Related Articles